Skip to main content

Table 4 Median GDMI stratified by different histopathologic characteristics for normal disease, tumor, and their ratios.

From: A high-throughput and sensitive method to measure Global DNA Methylation: Application in Lung Cancer

Characteristics

Enzymes

Normal Disease

p-value

Tumor

p-value

Tumor/Normal Disease

p-value

  

(Median)

 

(Median)

 

(Median)

 

Stage

 

Stage IA

(n = 10)

Stage IB

(n = 7)

 

Stage IA

(n = 10)

Stage IB

(n = 7)

 

Stage IA

(n = 10)

Stage IB

(n = 7)

 
 

HinP1I

0.20

0.15

0.22

0.18

0.26

0.005**

0.92

1.74

0.006**

 

HypCH4IV

0.37

0.37

0.92

0.39

0.43

0.59

1.05

1.33

0.08*

 

HpaII

0.31

0.32

0.49

0.35

0.44

0.13

1.20

1.32

0.19

Grade of Differentiation

 

Well Diff

(n = 3)

Nonwell Diff

(n = 15)

 

Well Diff

(n = 3)

Nonwell Diff

(n = 15)

 

Well Diff

(n = 3)

Nonwell Diff

(n = 15)

 
 

HinP1I

0.20

0.20

0.31

0.19

0.25

0.17

1.11

1.21

0.86

 

HypCH4IV

0.37

0.37

0.77

0.29

0.44

0.10*

0.79

1.14

0.04**

 

HpaII

0.31

0.32

0.68

0.28

0.41

0.01**

0.82

1.33

0.01**

Tumor Size

 

T1

(n = 10)

T2

(n = 8)

 

T1

(n = 10)

T2

(n = 8)

 

T1

(n = 10)

T2

(n = 8)

 
 

HinP1I

0.20

0.16

0.66

0.18

0.25

0.04**

0.99

1.47

0.04**

 

HypCH4IV

0.37

0.35

0.59

0.39

0.42

0.70

1.01

1.15

0.12

 

HpaII

0.32

0.32

0.62

0.32

0.43

0.08*

1.14

1.31

0.17

  1. Numbers in bold with asterisks indicate statistical significance of non-parametric Wilcoxon/Kruskal-Wallis tests with a threshold of p <= 0.05 (**) or p <= 0.10 (*).